Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)
This study has been completed.
Study NCT00034684 Information provided by Merck Sharp & Dohme Corp.
First Received on May 1, 2002. Last Updated on October 8, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Leukemia, Myeloid, Chronic
Additional conditions recognized in this trial
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
More general conditions related to this trial
Bone Marrow Diseases
Cell Transformation, Neoplastic
Immune System Diseases
Neoplasms by Histologic Type
Sponsors listed in this trial
Merck Sharp & Dohme Corp.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers